AngioDynamics, Inc. (ANGO)
| Market Cap | 471.53M |
| Revenue (ttm) | 307.31M |
| Net Income (ttm) | -27.71M |
| Shares Out | 41.22M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 201,319 |
| Open | 11.40 |
| Previous Close | 11.46 |
| Day's Range | 11.30 - 11.48 |
| 52-Week Range | 8.27 - 13.99 |
| Beta | 0.50 |
| Analysts | Strong Buy |
| Price Target | 19.33 (+68.97%) |
| Earnings Date | Apr 1, 2026 |
About ANGO
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device tha... [Read more]
Financial Performance
In fiscal year 2025, AngioDynamics's revenue was $292.50 million, a decrease of -3.76% compared to the previous year's $303.91 million. Losses were -$33.99 million, -81.56% less than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ANGO stock is "Strong Buy." The 12-month stock price target is $19.33, which is an increase of 68.97% from the latest price.
News
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript
AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript
AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
AngioDynamics, Inc. (NASDAQ: ANGO) will release earnings results for its second quarter before the opening bell on Tuesday, Jan. 6, 2026.
AngioDynamics: Growth Remains Under The Radar
AngioDynamics looks undervalued, with Med Tech segment growth in thrombus management, atherectomy, and NanoKnife driving the investment thesis. Consistent execution on revenue growth and margin improv...
AngioDynamics to Report Fiscal 2026 Second Quarter Results on January 6, 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Present at the 44th Annual J.P. Morgan Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics, Inc. (ANGO) Presents at UBS Global Healthcare Conference 2025 Transcript
AngioDynamics, Inc. ( ANGO) UBS Global Healthcare Conference 2025 November 10, 2025 8:00 AM EST Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO ...
AngioDynamics to Participate in the UBS Global Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics' NanoKnife® System Named to TIME's 2025 Best Inventions List
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics: Discounted Sales Multiple With Real Growth Engines
AngioDynamics, Inc. remains a Buy, trading at a steep discount to peers despite double-digit MedTech growth and improving margins. ANGO's Med Tech division now drives 47% of sales, with strong perform...
AngioDynamics, Inc. (ANGO) Q1 2026 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO) Q1 2026 Earnings Call October 2, 2025 8:00 AM EDT Company Participants James Clemmer - CEO, President & Director Stephen Trowbridge - Executive VP & CFO Conference C...
Nasdaq Surges 100 Points; AngioDynamics Posts Upbeat Q1 Results
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points.
AngioDynamics Reports Fiscal Year 2026 First Quarter Financial Results; Med Tech Growth of 26.1% Drives Continued Momentum
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
Top Wall Street Forecasters Revamp AngioDynamics Expectations Ahead Of Q1 Earnings
AngioDynamics, Inc. (NASDAQ:ANGO) will release earnings results for the first quarter, before the opening bell on Thursday, Oct. 2.
AngioDynamics to Report Fiscal 2026 First Quarter Results on October 2, 2025
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics: A MedTech Powerhouse Emerging From Legacy Overhaul
AngioDynamics has completed a strategic transformation, divesting non-core assets and focusing on high-growth MedTech platforms, driving accelerating revenue and margin improvement. Recent results con...
AngioDynamics to Present at the Canaccord Genuity 45th Annual Growth Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Enrolls First Patient in AMBITION BTK Trial Advancing Treatment for Critical Limb Ischemia
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics Announces Publication of PRESERVE Study of NanoKnife® System for Prostate Tissue Ablation in European Urology
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics, Inc. (ANGO) Q4 2025 Earnings Call Transcript
AngioDynamics, Inc. (NASDAQ:ANGO) Q4 2025 Earnings Conference Call July 15, 2025 8:00 AM ET Company Participants James C. Clemmer - CEO, President & Director Stephen A.